179 related articles for article (PubMed ID: 15151521)
1. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.
Urien S; Lokiec F
Br J Clin Pharmacol; 2004 Jun; 57(6):756-63. PubMed ID: 15151521
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients.
Urien S; Brain E; Bugat R; Pivot X; Lochon I; Van ML; Vauzelle F; Lokiec F
Cancer Chemother Pharmacol; 2005 Jan; 55(1):55-60. PubMed ID: 15258698
[TBL] [Abstract][Full Text] [Related]
3. Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program.
Chen R; Li J; Hu WW; Wang ML; Zou SL; Miao LY
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1111-23. PubMed ID: 24061864
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of cisplatin in adult cancer patients.
de Jongh FE; Gallo JM; Shen M; Verweij J; Sparreboom A
Cancer Chemother Pharmacol; 2004 Aug; 54(2):105-12. PubMed ID: 15127229
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.
Deporte-Fety R; Simon N; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Urien S
Cancer Chemother Pharmacol; 2004 Mar; 53(3):233-8. PubMed ID: 14634791
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.
Rezai K; Urien S; Isambert N; Roche H; Dieras V; Berille J; Bonneterre J; Brain E; Lokiec F
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1529-36. PubMed ID: 21519841
[TBL] [Abstract][Full Text] [Related]
12. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients.
Ishibashi T; Yano Y; Oguma T
Br J Clin Pharmacol; 2003 Aug; 56(2):205-13. PubMed ID: 12895194
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of oral busulfan in children.
Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.
Loos WJ; de Jongh FE; Sparreboom A; de Wit R; van Boven-van Zomeren DM; Stoter G; Nooter K; Verweij J
J Clin Oncol; 2006 Apr; 24(10):1499-506. PubMed ID: 16574999
[TBL] [Abstract][Full Text] [Related]
18. Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block.
Rapp HJ; Molnár V; Austin S; Krohn S; Gädeke V; Motsch J; Boos K; Williams DG; Gustafsson U; Huledal G; Larsson LE
Paediatr Anaesth; 2004 Sep; 14(9):724-32. PubMed ID: 15330953
[TBL] [Abstract][Full Text] [Related]
19. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
de Jongh FE; Verweij J; Loos WJ; de Wit R; de Jonge MJ; Planting AS; Nooter K; Stoter G; Sparreboom A
J Clin Oncol; 2001 Sep; 19(17):3733-9. PubMed ID: 11533095
[TBL] [Abstract][Full Text] [Related]
20. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
